A recent study reveals that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who end traditional lifestyle programs.
Research printed in a prominent health publication shows that while obese people frequently drop substantial amounts of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Users buying such drugs must be aware of the risk of rapid rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
This pace of recovery means a reversion to original weight in about 18 months.
Weighing Therapies
The analysis, which examined 37 of trials involving thousands of patients, compared the results of the injectable medications with other pills.
Scientists note that people who lose weight through dieting typically have a more gradual creep back—around 100 grams monthly—post-intervention.
Explaining the Fast Rebound
Doctors believe the way of the jabs explains the accelerated weight return.
The injections copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels far above than normal may cause the system to produce less of its endogenous hormone, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication results in hunger is no longer kept in check, making overeating much more probable."
An Ongoing Disease?
The NHS recommend the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes.
A number of clinicians say that, considering the significant potential of relapse, the treatment might need to be life-long.
This view is echoed by pharmaceutical companies, who note that the results "emphasize the persistent character of excess weight," similar to managing diseases like diabetes.
Patient Experiences
People who have discontinued the medication report a sudden resurgence of appetite.
"It was like a switch activating and I was suddenly starving," said a patient.
This challenge is worsened if individuals have not developed permanent dietary or behavioural modifications during treatment.
Significant Use
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Use is higher among females than males.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while the jabs are potent tools for weight loss, they are not a permanent cure and long-term success relies on integrated behavioural changes.
